The Jill Roberts Center for Inflammatory Bowel Disease (JRC) has an active clinical trials and translational research program. See below for a list of actively recruiting clinical trials and translational research trials.
Patients who are interested in participating in a clinical trial should contact Fatiha Chabouni at (212) 746-5109.
Crohn's Disease
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year (SEAVUE)
Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease (DINE-CD)
Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD) (BERGAMOT)
Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease (ADMIRE-CD-II)
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF‑06700841 In Subjects With Moderate To Severe Crohn's Disease
Inflammatory Bowel Disease
The Role of Inflammatory Markers in Predicting Clinical Course of Inflammatory Bowel Disease
Correlative Studies on Hemangiogenesis in Inflammatory Bowel Disease (IBD) and Associated Colon Neoplasia
The Multi-Center African American IBD (Inflammatory Bowel Disease) Study (MAAIS)
Patient attitudes regarding de-escalation of IBD therapies
Utilization of Serologic and Genetic Testing for the Management of Inflammatory Bowel Diseas
A retrospective, multi-center cohort study of biologic and small molecule medications for moderate to severe ulcerative colitis and Crohn's disease
Microbiota in IBD-associated Spondyloarthritis
IBD Biobank for Microbiome, Genetic, and Immune Cell Analysis
The Effect of Continuing Medical Education on Compliance with Inflammatory Bowel Disease Quality Metrics
SMART IBD: Stratifying Medical response and Refractory to Treatment disease in IBD
SAPPHIRE: Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients With a HistoRy of CancEr
Gut Microbiota and Host Immunity in Inflammatory Bowel Disease (IBD) Patients With Spondyloarthropathy
A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease
Ulcerative Colitis
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
Protocol GA28951: An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase III Studies
Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis (ENTERPRET)
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
Efficacy and Safety of AbGn-168H in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis
A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors